Glenmark Pharmaceuticals acquires certain OTC drugs from Wockhardt in US

Glenmark Pharma on Tuesday said its US subsidiary has acquired a portfolio of approved over-the-counter (OTC) abbreviated new drug applications (ANDAs) from Wockhardt.
Glenmark didn't disclose the financial details of the acquisition.

The company said the acquired ANDAs will help to expand its US OTC portfolio.

The acquired ANDAs include famotidine tablets 10 mg and 20 mg, cetirizine hydrochloride tablets 5 mg and 10 mg, lansoprazole delayed-
release capsules 15 mg and olopatadine hydrochloride ophthalmic solution 0.1%.

“The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world," said Sanjeev Krishan, President of Glenmark's US business

"Our acquisition of these ANDAs represents the continued expansion of our business into the OTC market here in the US and commitment to ensuring patients have access to high quality, affordable medicines,” Krishan added.

Glenmark’s current portfolio consists of 175 products authorized for distribution in the US and 48 ANDAs pending approval with the USFDA.

In addition to these internal filings, Glenmark said it continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.